Ajanta Pharma launches of anti-dementia drug memantine HCl in US
The company has launched the drug, which is a generic version of Forest Laboratories' Namenda tablet, in two strengths - 5 mg & 10 mg tablets
 "Ajanta Pharma launches of anti-dementia drug memantine HCl in US")
Ajanta Pharma Ltd, through its wholly owned subsidiary Ajanta Pharma USA Inc, has launched anti-dementia drug, memantine hydrochloride tablet, in the US market. Memantine hydrochloride is a bioequivalent generic version of Forest Laboratories Inc’s Namenda. Ajanta Pharma has launched the drug in two strengths – 5 mg & 10 mg tablets - to address different levels of treatment.
Memantine hydrochloride tablet is part of an ever-growing portfolio of products that Ajanta has developed for the US market. To date, the US Food & Drug Administration (U.S FDA) has granted Ajanta Pharma 10 final approvals and 2 tentative approvals for its abbreviated new drug application (ANDA). Additional 14 ANDAs are pending approval from the FDA.
Memantine hydrochloride tablet is part of an ever-growing portfolio of products that Ajanta has developed for the US market. To date, the US Food & Drug Administration (U.S FDA) has granted Ajanta Pharma 10 final approvals and 2 tentative approvals for its abbreviated new drug application (ANDA). Additional 14 ANDAs are pending approval from the FDA.